ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RYTM vs BLTE // EV/EBITDA & P/E VALUATION

Rhythm Pharmaceuticals Inc. (NASDAQ) VS. Belite Bio Inc (NASDAQ) • 15-METRIC TALLY: RYTM 2 — BLTE 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RYTM VS. BLTE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RYTM BLTE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 89.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -29.60% -15.90% -13.70 BLTE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -1.82% -0.61% -1.21 BLTE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -0.10% — — TIE /net-margins <GO>
Revenue Growth (YoY) 45.80% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 14.33 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 2/9 +3.00 RYTM /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.0 50.3 -0.30 BLTE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.96 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 33.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $6.37B $6.23B $141.9M RYTM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RYTM REV BLTE REV RYTM GROSS % BLTE GROSS % RYTM FCF BLTE FCF
FY 2025 $189.8M $235.8M 89.7% — -$116.6M -$37.1M
FY 2024 $130.1M $112.0M 89.7% — -$113.9M -$29.4M
FY 2023 $77.4M $88.7M — — -$139.6M -$29.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RYTM // BETA 0.96
BLTE // BETA —